FDA Approves Labeling Changes, Boxed Warning for Efalizumab
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Labeling Changes, Boxed Warning for Efalizumab

ROCKVILLE, Md -- October 16, 2008 -- The US Food and Drug Administration (FDA) has announced labeling changes, including a Boxed Warning, to efalizumab (Raptiva) to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML).

The labeling changes are based on the FDA's post-market surveillance. The FDA is also requiring the submission of a Risk Evaluation and Mitigation Strategy (REMS), which will include a Medication Guide for patients and a timetable for assessment of the REMS.

The FDA's Office of Surveillance and Epidemiology has received reports of serious infections leading to hospitalisations, and deaths in some cases, in patients using efalizumab.

The now-required Boxed Warning will highlight the risk of bacterial sepsis, viral meningitis, invasive fungal disease, PML, and other opportunistic infections.

"As part of FDA's monitoring of the life-cycle of approved products, the agency received reports of serious infections in some patients taking [efalizumab]. These reports led to our decision to highlight these risks in the drugs labeling," said Janet Woodcock, FDA's Center for Drug Evaluation and Research, Rockville, Maryland.

"Doctors and other prescribers should carefully evaluate and weigh the risk/benefit profile of [efalizumab] for patients who would be more susceptible to these risks."

Health care professionals should monitor patients treated with [efalizumab] for the signs and symptoms of infection, PML, anaemia, thrombocytopenia, or the worsening of their psoriasis or arthritis, and also instruct patients to report any such signs and symptoms to them without delay.

Consumers and health care professionals can report adverse events to the FDA's MedWatch program at 800-FDA-1088, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or online at www.fda.gov/medwatch/report.htm.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities